Hu Pei, MD, is Professor of Clinical Pharmacology and Director, Phase I Unit, Beijing Key Laboratory of Clinical PK/PD, Clinical Pharmacological Research Center, Peking Union Medical College Hospital. She has engaged in the teaching and research of clinical pharmacology, primarily in early clinical research and quantitative pharmacology of new drugs, for two decades. Professor Pei previously engaged in postdoctoral research at the Department of Medicinal Chemistry, University of Washington (US) through funding from the US National Institutes of Health Fogarty Fellowship, and has published more than 70 peer-reviewed articles. She earned her Doctorate in Medicine from Peking Union Medical College.

George Liu, PhD, is Head of Early Development and Scientific Operation at Harbour BioMed. Before joining HBM, he served as Director of Clinical Pharmacology for Novartis Oncology, responsible for clinical pharmacology in early clinical development and lifecycle management in oncology. Dr. Liu previously held positions of increasing importance in nonclinical and clinical pharmacokinetics for Sanofi, GSK, and Guilford Pharmaceuticals. He is a member of the Professional Committee of Pharmacometrics of the China Pharmacological Society, and of the American Association of Pharmaceutical Scientists. Dr. Liu earned his PhD in Medicinal Chemistry and Molecular Pharmacology from the Purdue University School of Pharmacy and Pharmaceutical Sciences.

Dr. Ling Su is a Research Fellow in Shengyang Pharmaceutical University Yeehong Business School and a Venture Partner in Lilly Asia Ventures (LAV). He has 30 years of experience in drug regulatory and development. He had worked in various R&D management positions in the pharma industry, including Medical Director at MSD, Pharma Development Director at Roche, VP for Clinical Research Asia Pacific at Wyeth, and SVP and Head of Pharma Development China at Novartis. Prior to that, he worked in the Chinese regulatory agency and CDER, US FDA. He is a Fellow of DIA and was the President of DIA (2012-2013). Ling holds BS in pharmacology from Shanghai Medical University and PhD in Epidemiology from University of North Carolina at Chapel Hill, USA.

Zaiqi Wang, MD, PhD, is Site Head, Roche Innovation Center Shanghai. Dr. Wang has more than twenty years of international clinical trial experience, from first-in-human to phase 4 clinical trials, in numerous therapeutic fields for other multinational companies such as Eli Lilly, Schering-Plough, and Merck. He formerly served as Director for the MSD Clinical Translational Medicine Center established in Singapore, and as head of clinical research for Merck China. Dr. Wang graduated from Henan Medical University.

Xia Jie Lai, PhD, serves as Director, Professor, and Doctoral Tutor of the Department of Health Statistics at the Air Force Military Medical University (Fourth Military Medical University), and as biostatistics review and consultation expert for the State Food and Drug Administration. He has contributed to dozens of clinical trials for chemical drugs, Chinese medicine, biological products, and medical devices; his current work includes statistical design and analysis of large-scale clinical trials for vaccines. Dr. Lai’s work has been funded through seven National Natural Science Foundation projects, and he participated in three research projects in the Eleventh Five-Year Plan for Science and Technology Innovation.